Episode Details
Back to Episodes
Novartis's HARBOR Miss Tests Confidence in the Growth Plan & Rasonque's Access Hurdles
Description
Novartis's del-desiran missed HARBOR's primary endpoint in myotonic dystrophy, adding pressure to a growth plan already facing setbacks. Roivant and Pulmovant's mosliciguat data advance Monday's PHocus preview, while AstraZeneca, Pharvaris, Amgen, Inhibrx and Bristol Myers add clinical updates across lung disease, hereditary angioedema and cancer. BrainChild Bio's financing, the proposed Sernova-Seraxis merger and Intellia's lonvo-z Priority Review round out the slate. Two resolved Rasonque access cases show why Revolution Medicines' pancreatic cancer launch requires more than approval: patients still need to navigate authorization, support and dispensing.
Alex Mercer and Maya Patel host the Daily Roundup for September 8. Get the daily rundown in your inbox — subscribe at thepharmacloseout.com.